Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News
Kupfer en mass...: 10 Prozent-Kupfer an der Oberfläche! - Diese Entdeckung könnte zur heißesten Kupferstory des Jahres werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW | ISIN: KYG2588M1006 | Ticker-Symbol: PH4
Frankfurt
18.07.25 | 17:52
0,725 Euro
+8,21 % +0,055
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,7050,74018.07.
0,7200,73518.07.

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN1
MiCSTONE PHARMA-B (02616): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE2
10.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL FOR LOCALIZED MANUFACTURING OF GAVRETO (PRALSETINIB) IN CHINA2
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
09.07.CSTONE PHARMA-B (02616): PLACING OF NEW SHARES UNDER GENERAL MANDATE3
08.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE SIGNS EXCLUSIVE LICENSE AGREEMENT WITH ISTITUTO GENTILI FOR SUGEMALIMAB IN WESTERN EUROPE AND ...5
07.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CLINICAL PROGRESS UPDATE ON CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY)5
04.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON GLOBAL MULTICENTER PHASE III STUDY OF NOFAZINLIMAB IN HEPATOCELLULAR CARCINOMA3
03.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE UNVEILS TWO BISPECIFIC ANTIBODY TARGETS FOR AUTOIMMUNE/INFLAMMATORY DISEASES5
25.06.CSTONE PHARMA-B (02616): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE4
25.06.CSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION3
25.06.CSTONE PHARMA-B (02616): (1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025; (2) RETIREMENT AND RESIGNATION OF DIRECTORS; AND (3) CHANGE ...2
19.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - LONG-TERM SURVIVAL DATA OF GEMSTONE-302 TRIAL ON SUGEMALIMAB PUBLISHED IN THE LANCET ONCOLOGY9
13.06.CSTONE PHARMA-B (02616): ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES3
03.06.CSTONE PHARMA-B (02616): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR AND ...6
03.06.CSTONE PHARMA-B (02616): FORM OF PROXY FOR ANNUAL GENERAL MEETING1
03.06.CSTONE PHARMA-B (02616): NOTICE OF ANNUAL GENERAL MEETING-
06.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTED FIVE LATEST STUDIES AT 2025 AACR ANNUAL MEETING4
28.04.CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20242
28.04.CSTONE PHARMA-B (02616): 2024 ANNUAL REPORT4
11.04.CSTONE PHARMA-B (02616): (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP1
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1